Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Kura Oncology, Inc. (NASDAQ: KURA).

Full DD Report for KURA

You must become a subscriber to view this report.


Recent News from (NASDAQ: KURA)

Daily Insider Ratings Round Up 12/6/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...
Source: SeekingAlpha
Date: December, 10 2018 00:30
Kura Oncology: A Winner At ASH, What To Expect In 2019
Shares of Kura Oncology ( KURA ) have risen by only 17% since my initial article highlighted early clinical results for lead drug candidate tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC). The stock has lost nearly 40% sinc...
Source: SeekingAlpha
Date: December, 09 2018 15:49
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma
– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL – – AITL and other PTCL patients with high CXCL12 expression experienced 50% ORR and 90% clinical benefit with tipifarnib after median of three prior therapies &#x...
Source: GlobeNewswire
Date: December, 02 2018 12:00
Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled...
Source: GlobeNewswire
Date: November, 06 2018 07:30
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2018 Results - Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q3 2018 Earnings Conference Call November 5, 2018 4:30 p.m. ET Executives Pete De Spain - VP, IR and Corporate Communications Troy Wilson - President and CEO Marc Grasso - CFO and Chief Business Officer Antonio Gualberto - Head, Development and Chief ...
Source: SeekingAlpha
Date: November, 05 2018 20:48
Kura Oncology beats by $0.01
Kura Oncology (NASDAQ: KURA ): Q3 GAAP EPS of -$0.40 beats by $0.01. More news on: Kura Oncology, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 05 2018 16:17
Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upc...
Source: GlobeNewswire
Date: November, 05 2018 16:05
Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...
Source: GlobeNewswire
Date: November, 05 2018 07:30
Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company’s lead product candidate, tipifarnib, ...
Source: GlobeNewswire
Date: November, 01 2018 09:00
Kura Oncology to Report Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2018 financial results after the close of U.S. financ...
Source: GlobeNewswire
Date: October, 29 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1417.5017.3517.7017.25196,251
2017-09-1311.1011.6512.1010.951,018,005
2017-09-1211.5511.1011.7010.85988,073
2017-09-1112.5511.6513.4510.804,547,971
2017-09-089.3511.8013.809.3020,286,638

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1416,43923,81269.0366Short
2018-12-1334,73064,98553.4431Short
2018-12-1214,79626,62855.5656Short
2018-12-1115,97083,75419.0677Cover
2018-12-1023,75136,66364.7819Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KURA.


About Kura Oncology, Inc. (NASDAQ: KURA)

Logo for Kura Oncology, Inc. (NASDAQ: KURA)

Kura Oncology is a clinical stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor. The company s preclinical pipeline includes KO , an ERK inhibitor, and a menin MLL inhibitor program.

 

Contact Information

 

 

Current Management

  • Troy Edward Wilson / CEO
  • Heidi Henson / CFO
  • Anna Nadolski / IR
  • Troy Edward Wilson / Chairman
  • Faheem Hasnain /
  • Robert Hoffman / Director
    • Robert E. Hoffman has served as a member of our Board of Directors since September . Mr. Hoffman is CFO of AnaptysBio, a position he has held since July . Mr. Hoffman was the Senior Vice President, Finance and CFO of Arena Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, until July and has held other finance and accounting management roles at Arena since , except that from March to August , Mr. Hoffman served as Chief Financial Officer for Polaris Group, a privately held drug development company. Mr. Hoffman is currently a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company and Kura Oncology, Inc. a biopharmaceutical company. He also currently serves as a member of the Financial Accounting Standards Board s Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. In addition, Mr. Hoffman is a member and a former director and President of the San Diego Chapter of Financial Executives International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. inactive in the State of California.
  • Thomas Malley /

Current Share Structure

  • Market Cap: $568,682,443 - 05/17/2018
  • Authorized: 200,000,000 - 08/27/2015
  • Issue and Outstanding: 33,353,809 - 03/09/2018

 


Recent Filings from (NASDAQ: KURA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 06 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 31 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: July, 10 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: July, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 02 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 28 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 27 2018
Registration of up to an additional 20% of securities for any offering registered on a S-3
Filing Type: S-3MEFFiling Source: edgar
Filing Date: June, 27 2018

 

 


Daily Technical Chart for (NASDAQ: KURA)

Daily Technical Chart for (NASDAQ: KURA)


Stay tuned for daily updates and more on (NASDAQ: KURA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: KURA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KURA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of KURA and does not buy, sell, or trade any shares of KURA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/